Tirzepatide has a higher affinity with GLP-1R than GLP-1 does (pIC 50 : 8.90 vs 8.62), and its cAMP activation activity is significantly lower (12 decrease in pEC 50 )
[10] Recommended by NICE for use within specialist weight management services (subject to eligibility criteria)
Why are injectable formulations still dominant despite oral options
However, the broad GLP-1 agonist class has generally shown real-world effectiveness that tracks reasonably close to clinical trial results, with some attenuation
That is the real job many GLP-1 users are trying to solve: less mental load, fewer moving parts, and one place to understand what is happening around the medication
Safe and Trustworthy With a solid foundation supported by an array of extensive clinical trials, Semaglutide has emerged as a remarkably effective and secure option for weight management